Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

January 31, 2018

Conditions
Myasthenia Gravis
Interventions
DRUG

HIZENTRA ®

Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.

Trial Locations (5)

14203

University at Buffalo, Buffalo

66160

University of Kansas Medical Center, Kansas City

75390

University of Texas Southwestern Medical Center, Dallas

85018

Phoenix Neurological Associates, Phoenix

Unknown

University of Toronto, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

lead

Mazen Dimachkie, MD

OTHER